AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback